Clinical Trial

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Study acronym: TRIM-Line
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-08-25; most recent amendment 2025-07-03.
Status change: Not Yet Recruiting → Recruiting 2022-10-01
Trial Details
NCT Number NCT05029063
Lead Sponsor Ottawa Hospital Research Institute
Conditions Venous Thromboembolism, Cancer
Enrollment 1,828 participants
Start Date 2022-10-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-09